WO2001032646A2 - Sulfonamide derivatives - Google Patents
Sulfonamide derivatives Download PDFInfo
- Publication number
- WO2001032646A2 WO2001032646A2 PCT/EP2000/010911 EP0010911W WO0132646A2 WO 2001032646 A2 WO2001032646 A2 WO 2001032646A2 EP 0010911 W EP0010911 W EP 0010911W WO 0132646 A2 WO0132646 A2 WO 0132646A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- description
- compound
- group
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- This invention relates to novel sulfonamide compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.
- WO 98/27081 discloses sulfonamide compounds that possess 5-HTg receptor antagonist activity and which are claimed to be useful in the treatment of various CNS disorders.
- WO 94/21619 and EP 0701819 both disclose a series of naphthalene derivatives that are claimed to be 5-HTJA receptor ligands.
- the present invention therefore provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:
- A is a single bond, a Ci .galkylene or a C2-6 a lkenylene group
- R! is halogen, C ⁇ . ⁇ alkyl optionally substituted by one or more halogen atoms, C3_6cycloalkyl, phenyl, COC galkyl, C ⁇ galkoxy, OCF3, hydroxy, hydroxyCi.galkyl, hydroxyC 1.galkoxy, Ci.galkoxyCi.galkoxy, nitro, amino, Ci .galkylamino or diCi _ ⁇ alkylamino;
- R.2 is hydrogen, Ci. _6alkyl or together with a group R ⁇ forms a group -(CR6R7)p- where R6 and R? are independently hydrogen or Cj.galkyl and p is 2, 3 or 4;
- R3 is C1. ⁇ alkyl optionally substituted by one or more halogen atoms, halogen, C1.
- R2 forms a group -(CR ⁇ R ⁇ )p- as defined above; m is 0, 1 or 2; R4 is a group -X-R ⁇ where X is a single bond, CH2, O, NH or N-C j .galkyl and R ⁇ is an optionally substituted 5- to 7-membered heterocyclic ring or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, sulphur or oxygen; Q is a phenyl ring or is a 6 membered heteroaryl ring containing one or two nitrogen atoms.
- C 1 -6alkyl groups may be straight chain or branched.
- the term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.
- P When P is naphthyl this is intended to denote both naphth-1-yl and naphth-2-yl groups.
- P When P is a 5 or 6-membered heteroaryl ring suitable examples include thienyl, furyl, pyrrolyl, triazolyl, diazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl.
- P When P is a bicyclic heteroaryl ring suitable examples include indolyl, benzofiiryl, benzothienyl, quinolinyl and isoquinolinyl.
- P When P is a tricyclic heteroaryl ring a preferred example is dibenzo furyl.
- the heteroaryl rings can be linked to the remainder of the molecule via any suitable carbon atom or, when present, a nitrogen
- P is phenyl, naphthyl, benzofiiryl or benzothienyl.
- R1 When n is more than 1 the groups R1 can be the same or different.
- R! is halogen (particular chloro or bromo), or a C ⁇ _6alkyl group optionally substituted by one or more halogen atoms, for example, methyl, ethyl, isopropyl, t-butyl or trifluoromethyl.
- n 0, 1, 2 or 3, particularly 1 or 2.
- R2 together with a group R ⁇ forms a further group -(CR6R7)p- both of the groups R6 and R are preferably hydrogen and p is preferably 2.
- R ⁇ is preferably hydrogen.
- a substituent R ⁇ can be attached at any unsubstituted carbon atom within the fused ring.
- m is more than 1 the groups R ⁇ can be the same or different. It will be appreciated that when the R2/R3 groups are linked together, the group R ⁇ must be attached to one of the carbon atoms of the fused ring with an ortho relationship with respect to the sulfonamide linkage. Preferably m is 0.
- the group R ⁇ can be attached at any unsubstituted carbon atom within the ring
- R5 is a 5- to 7- membered heterocyclic ring
- suitable examples include piperazinyl, piperidinyl, pyrrolidinyl and morpholinyl.
- the 5- to 7- membered heterocyclic rings can be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom.
- X is O, NH or N-C j.galkyl then the 5- to 7- membered heterocyclic ring must be linked to the rest of the molecule via a carbon atom.
- R5 is a bicyclic heterocyclic ring
- Optional substituents for rings within the definition of R ⁇ which can be present on carbon and/or nitrogen atoms, include Cj.galkyl, in particular methyl.
- R ⁇ is an unsubstituted piperazine or N-methyl piperazine attached to the rest of the molecule via a suitable nitrogen atom.
- Q is a phenyl ring or is a 6 membered heteroaryl ring containing one or two nitrogen atoms.
- Q together with the phenyl ring to which it is fused, forms a quinoline, isoquinoline or quinazoline ring.
- Particular preferred compounds of this invention include:
- the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic .
- acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic .
- Compounds of formula (I) may also form solvates such as hydrates, and the invention also extends to these forms. When referred to herein, it is understood that the term 'compound of formula (I)' also includes these forms.
- Certain compounds of formula (I) are capable of existing in stereoisomeric forms including diastereomers and enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
- the different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis.
- the invention also extends to any tautomeric forms and mixtures thereof.
- the present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises the coupling of a compound of formula (II) or protected derivatives thereof:
- Suitable leaving groups include halogen, in particular chloro.
- the reaction of a compounds of formulae (II) and (III) is carried out by mixing the two reagents together, optionally in an inert solvent such as dichloromethane or acetone. Such a reaction may be carried out in the presence of base.
- an inert solvent such as dichloromethane or acetone.
- Such a reaction may be carried out in the presence of base.
- Suitable protecting groups and methods for their attachment and removal are conventional in the art of organic chemistry, such as those described in Greene T.W.
- suitable protecting groups for the piperazine group include BOC, COCCI3 , COCF3 and methyl the latter of which may be removed by treatment with 1-chloroethyl chloroformate according to standard procedures.
- N-substituted piperazines can be prepared by acylation or alkylation of the appropriate NH-piperazine compound according to standard procedures.
- compositions of formula (I) and their pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.
- Compounds of formula (I) and their pharmaceutically acceptable salts have
- 5-HTg receptor antagonist activity and are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, cognitive memory disorders (e.g. age related cognitive decline and/or Alzheimers disease), Parkinson's Disease, ADHD (attention deficit / hyperactivity disorder), sleep disorders (including disturbances of circadian rhythm), feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
- Compounds of the invention are also expected to be of use in the treatment of certain GI (gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome).
- the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders.
- the invention provides a compound of general formula (I) or a pharmaceutically acceptable salt for use in the treatment or prophylaxis of schizophrenia,
- ADHD ADHD, cognitive memory enhancement, anxiety and/or depression.
- the invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a safe and therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
- the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of the above disorders.
- the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
- Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
- the tablets may be coated according to methods well known in normal pharmaceutical practice.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
- fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
- the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
- the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
- the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
- suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.5 to 100 mg; and such therapy may extend for a number of weeks or months.
- 6-Nitroquinoline-l -oxide (24.5g, 0.13mmol) was added portionwise to ice-cooled , stirred phosphorus oxychloride (150ml). The mixture was then heated to reflux under argon for 3 hours to produce a precipitate. After cooling the mixture to room temperature, it was slowly poured onto stirred ice (1.5Kg) then with maintained cooling it was neutralised with 40% NaOH solution, resulting in a solid precipitating which was filtered and washed with water (6 x 200ml). The solid was dried at 60°C under vacuum to afford crude material which was purified by column chromatography over silica gel eluting with dichloromethane to give the following isomeric compounds:
- N-Methylpiperazine (13ml, 0.17mol) was added dropwise to a stirred solution of 4- chloro-6-nitroquinazoline (Yakugaku Zasshi, 1974, 94(4), 417-423) (2.44g, 11. ⁇ mmol) in dry dichloromethane (60ml).
- This compound was prepared from l-(4-chloro-phenylsulfanyl)-3-methyl-butan-2-one
- Example 2 The following hydrochloride compounds (E8-E26) (Table 2) were prepared as described in Example 7 by reaction of the appropriate sulfonyl chloride derivative with 6-amino-4- (4- tert-butoxycarbonylpiperazin-l-yl)quinoline (D7).
- the sulfonyl chloride used in the preparation of Example 9 is described in Description 24.
- Other sulfonyl chlorides are prepared as indicated: Example 10 (D 16 and D 19), El 3 (D25), El 5 (D17 and D18), El 6 (D20 and D22), E17 (D21 and D23), E18 (D30 and D31), E21 (D36), E24 (D32 and D33), E25 (D34 and D35).
- Example 27 l-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-8-(4-methyl-piperazin-l-yI)- 2,3-dihydro-lH-pyrrolo[2,3-g]quinoline Hydrochloride (E27)
- E27 A solution of 5 -chloro-3 -methyl-benzothiophene-2-sulfonyl chloride (75mg, 0.27mmol) and 8-(4-methyl-piperazin-l-yl)-2,3-dihydro-lH-pyrrolo[2,3-g]quinoline (D17)(72mg, 0.27mmol) in 1,2-dichloroethane was refluxed for 5 hours under argon.
- Example 4 The following hydrochloride compounds (E31-E34)(Table 4) were prepared as described in Example 7 by reaction of the appropriate sulfonyl chloride derivative with 6-amino-4- (4-tert-butoxycarbonylpiperazin-l-yl)-3 -methyl quinoline (D42).
- the sulfonyl chloride used to prepare Example 33 is described in Descriptions D19 and D16.
- the hydrochloride compounds (E36, E37)(Table 5) were prepared as described in Example 35 by reaction between the appropriate sulfonyl chloride and quinoline derivatives.
- the hydrochloride compounds (E38-E41) were prepared as described in Example 7 and when appropriate the compounds were purified by column chromatography. The descriptions of the preparations of the quinoline derivatives used to derive these examples are indicated as follows: E36 (D44), E37 (D27), E38 (D47), E39 (D50), E40 (D57), E41 (D53).
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00974509A EP1228066A2 (en) | 1999-11-05 | 2000-11-02 | Sulfonamide derivatives |
JP2001534797A JP2003513085A (en) | 1999-11-05 | 2000-11-02 | New compound |
AU12787/01A AU1278701A (en) | 1999-11-05 | 2000-11-02 | Novel compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9926302.2 | 1999-11-05 | ||
GBGB9926302.2A GB9926302D0 (en) | 1999-11-05 | 1999-11-05 | Novel compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001032646A2 true WO2001032646A2 (en) | 2001-05-10 |
WO2001032646A3 WO2001032646A3 (en) | 2001-12-27 |
Family
ID=10864071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/010911 WO2001032646A2 (en) | 1999-11-05 | 2000-11-02 | Sulfonamide derivatives |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1228066A2 (en) |
JP (1) | JP2003513085A (en) |
AU (1) | AU1278701A (en) |
GB (1) | GB9926302D0 (en) |
WO (1) | WO2001032646A2 (en) |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002100822A1 (en) | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
WO2003037887A1 (en) * | 2001-11-01 | 2003-05-08 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
WO2003039547A1 (en) | 2001-11-09 | 2003-05-15 | Biovitrum Ab | Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake |
WO2003068752A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | Benzenesulfonamide derivatives as antipsychotic agents |
WO2003068751A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5-ht6 receptor affinity for the reatment of cns disorders |
WO2004000828A1 (en) * | 2002-06-20 | 2003-12-31 | Biovitrum Ab | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
WO2004031181A1 (en) * | 2002-10-07 | 2004-04-15 | Glaxo Group Limited | Sulfonamide derivatives as antipsychotic agents |
US6825202B2 (en) | 2001-08-10 | 2004-11-30 | Syntex (U.S.A.) Llc | Arylsulfonyl derivatives with 5-HT6 receptor affinity |
WO2005021530A1 (en) * | 2003-08-29 | 2005-03-10 | Glaxo Group Limited | 8- (1-piperazinyl)- quinoline derivatives and their use in the treatment of cns disorders |
JP2005517705A (en) * | 2002-02-13 | 2005-06-16 | グラクソ グループ リミテッド | Benzenesulfonamide derivatives and their use as dopamine D3 and D2 receptor ligands |
WO2005058858A1 (en) * | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
JP2005533747A (en) * | 2002-02-05 | 2005-11-10 | ノボ ノルディスク アクティーゼルスカブ | Novel aryl and heteroaryl piperazines |
JP2005536551A (en) * | 2002-06-20 | 2005-12-02 | ビオヴィトルム・アクチボラゲット | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
US7084156B2 (en) | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
WO2007004960A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer’s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson’s disease |
WO2007004959A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease |
CN1315809C (en) * | 2002-03-27 | 2007-05-16 | 葛兰素集团有限公司 | Quinoline derivatives and their use as 5-HT6 ligands |
US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
US7262192B2 (en) | 2003-04-29 | 2007-08-28 | Pfizer Inc. | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors |
EP1837332A1 (en) * | 2006-03-23 | 2007-09-26 | Laboratorios Del Dr. Esteve, S.A. | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
WO2007108744A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators |
WO2007108743A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators ii |
EP1897881A2 (en) | 2002-06-20 | 2008-03-12 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
US7462640B2 (en) | 2003-07-30 | 2008-12-09 | Laboratorios Del Dr. Esteve S.A. | Indol-6yl sulfonamide derivatives, their preparation and their use as 5-HT-6 as modulators |
US7569572B2 (en) | 2004-04-07 | 2009-08-04 | Pfizer Inc | Pyrazolo[4,3-D]pyrimidines |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
EP2116547A1 (en) * | 2008-05-09 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands |
WO2010032258A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl sulfonamide amine compounds and their use as 5-ht6 ligands |
US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US7820675B2 (en) | 2003-12-19 | 2010-10-26 | Biovitrum Ab | Benzofuran compounds |
US7923566B2 (en) | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
US7960374B2 (en) | 2006-10-30 | 2011-06-14 | Proximagen Limited | Tricyclic compounds, compositions, and methods useful in the treatment or prophylaxis of 5-HT6 receptor-related disorders |
US7964627B2 (en) | 2007-10-26 | 2011-06-21 | Suven Life Sciences Limited | Amino arylsulfonamide compounds and their use as 5-HT6 ligands |
WO2011083487A1 (en) | 2010-01-05 | 2011-07-14 | Suven Life Sciences Limited | Sulfone compounds as 5-ht6 receptor ligands |
US7999109B2 (en) | 2002-05-24 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
US7998981B2 (en) | 2005-08-12 | 2011-08-16 | Suven Life Sciences Limited | Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands |
US8003670B2 (en) | 2007-05-03 | 2011-08-23 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands |
US8097643B2 (en) | 2003-07-30 | 2012-01-17 | Laboratorios Del Dr. Esteve S. A. | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
US8344001B2 (en) | 2007-06-11 | 2013-01-01 | High Point Pharmaceuticals, Llc | Heterocyclic H3 antagonists |
US8378097B2 (en) | 2006-05-29 | 2013-02-19 | High Point Pharmaceuticals, Llc | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist |
US8470830B2 (en) | 2007-01-08 | 2013-06-25 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands |
US8501739B2 (en) | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US9808455B2 (en) | 2007-12-12 | 2017-11-07 | Axovant Sciences Gmbh | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US9840482B2 (en) | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US10059691B2 (en) | 2008-04-02 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1676841A1 (en) * | 2004-12-30 | 2006-07-05 | Esteve Laboratorios Dr. Esteve S.A. | Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments |
DE102007042154A1 (en) * | 2007-09-05 | 2009-03-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arylsulfonylaminomethyphosphonsäure derivatives, their preparation and their use as medicaments |
MX2010008778A (en) * | 2008-02-15 | 2010-08-30 | Hoffmann La Roche | 3-alkyl-piperazine derivatives and uses thereof. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021619A1 (en) * | 1993-03-16 | 1994-09-29 | Pfizer Inc. | Naphthalene derivatives |
WO1998027081A1 (en) * | 1996-12-19 | 1998-06-25 | Smithkline Beecham Plc | Sulphonamide derivatives, process for their preparation, and their use as medicaments |
-
1999
- 1999-11-05 GB GBGB9926302.2A patent/GB9926302D0/en not_active Ceased
-
2000
- 2000-11-02 EP EP00974509A patent/EP1228066A2/en not_active Withdrawn
- 2000-11-02 AU AU12787/01A patent/AU1278701A/en not_active Abandoned
- 2000-11-02 JP JP2001534797A patent/JP2003513085A/en not_active Withdrawn
- 2000-11-02 WO PCT/EP2000/010911 patent/WO2001032646A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021619A1 (en) * | 1993-03-16 | 1994-09-29 | Pfizer Inc. | Naphthalene derivatives |
WO1998027081A1 (en) * | 1996-12-19 | 1998-06-25 | Smithkline Beecham Plc | Sulphonamide derivatives, process for their preparation, and their use as medicaments |
Non-Patent Citations (2)
Title |
---|
BROMIDGE ET AL: "5-Chloro-N-(4-methoxy-3-piperazin-1-yl-ph enyl)-3-methyl-2-benzothioph enesulfonamide(SB-271046): A Potent, Selective, and Orally Bioavailable5-HT6 Receptor Antagonist" JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 42, no. 2, 28 January 1999 (1999-01-28), pages 202-205, XP002109186 * |
SLEIGHT ET AL: "The 5-hydroxytryptamine-6 receptor: localisation and function" EXPERT OPINION ON THERAPEUTIC PATENTS,GB,ASHLEY PUBLICATIONS, vol. 8, no. 10, 1 October 1998 (1998-10-01), pages 1217-1224, XP002093843 * |
Cited By (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA008476B1 (en) * | 2001-06-11 | 2007-06-29 | Биовитрум Аб | Substituted sulfonamide compounds, process for their use as medicaments for the treatment of cns disorders, obesity and type ii diabetes |
WO2002100822A1 (en) | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
US7572787B2 (en) | 2001-06-11 | 2009-08-11 | Biovitrum Ab | Substituted naphthalene sulfonamides |
US7144883B2 (en) | 2001-06-11 | 2006-12-05 | Biovitrum Ab | Bicyclic sulfonamide compounds |
JP2004536080A (en) * | 2001-06-11 | 2004-12-02 | ビオヴィトルム・アクチボラゲット | Substituted sulfonamide compounds, their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes |
KR100889718B1 (en) | 2001-06-11 | 2009-03-23 | 바이오비트럼 에이비(피유비엘) | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ? diabetes |
KR100888906B1 (en) * | 2001-06-11 | 2009-03-16 | 바이오비트럼 에이비(피유비엘) | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ⅱ diabetes |
US6825202B2 (en) | 2001-08-10 | 2004-11-30 | Syntex (U.S.A.) Llc | Arylsulfonyl derivatives with 5-HT6 receptor affinity |
WO2003037887A1 (en) * | 2001-11-01 | 2003-05-08 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
WO2003039547A1 (en) | 2001-11-09 | 2003-05-15 | Biovitrum Ab | Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake |
US7084156B2 (en) | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
JP2005533747A (en) * | 2002-02-05 | 2005-11-10 | ノボ ノルディスク アクティーゼルスカブ | Novel aryl and heteroaryl piperazines |
JP2005522452A (en) * | 2002-02-13 | 2005-07-28 | グラクソ グループ リミテッド | 7-Arylsulfonamide-2,3,4,5-tetrahydro-1H-benzo'diazepine derivatives having 5-HT6 receptor affinity for the treatment of CNS diseases |
JP2005526724A (en) * | 2002-02-13 | 2005-09-08 | グラクソ グループ リミテッド | Benzenesulfonamide derivatives as antipsychotic agents |
JP2005517705A (en) * | 2002-02-13 | 2005-06-16 | グラクソ グループ リミテッド | Benzenesulfonamide derivatives and their use as dopamine D3 and D2 receptor ligands |
WO2003068752A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | Benzenesulfonamide derivatives as antipsychotic agents |
WO2003068751A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5-ht6 receptor affinity for the reatment of cns disorders |
CN1315809C (en) * | 2002-03-27 | 2007-05-16 | 葛兰素集团有限公司 | Quinoline derivatives and their use as 5-HT6 ligands |
US8236947B2 (en) | 2002-03-27 | 2012-08-07 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7977337B2 (en) | 2002-03-27 | 2011-07-12 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7601837B2 (en) | 2002-03-27 | 2009-10-13 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
US7799774B2 (en) | 2002-03-27 | 2010-09-21 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7999109B2 (en) | 2002-05-24 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
US8030517B2 (en) | 2002-05-24 | 2011-10-04 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
US9035096B2 (en) | 2002-05-24 | 2015-05-19 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
EP1897876A2 (en) | 2002-06-20 | 2008-03-12 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
JP2005536551A (en) * | 2002-06-20 | 2005-12-02 | ビオヴィトルム・アクチボラゲット | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
WO2004000828A1 (en) * | 2002-06-20 | 2003-12-31 | Biovitrum Ab | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
SG156524A1 (en) * | 2002-06-20 | 2009-11-26 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
EA011581B1 (en) * | 2002-06-20 | 2009-04-28 | Биовитрум Аб (Пабл) | Heterocyclic compounds useful for the treatment of obesity and cns disorders |
EP1897876A3 (en) * | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
JP4754821B2 (en) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
EA008835B1 (en) * | 2002-06-20 | 2007-08-31 | Биовитрум Аб | Substituted sulfone and sulfonamides and pharmaceutical compositions based thereon useful for the treatment of obesity, type ii diabetes cns disorders |
EP1897881A2 (en) | 2002-06-20 | 2008-03-12 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
US7122538B2 (en) | 2002-10-07 | 2006-10-17 | Glaxo Group Limited | Sulfonamide derivatives as antipsychotic agents |
WO2004031181A1 (en) * | 2002-10-07 | 2004-04-15 | Glaxo Group Limited | Sulfonamide derivatives as antipsychotic agents |
US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
US9890148B2 (en) | 2002-11-18 | 2018-02-13 | Chemocentryx, Inc. | Aryl sulfonamides |
US8642808B2 (en) | 2002-11-18 | 2014-02-04 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US10364240B2 (en) | 2002-11-18 | 2019-07-30 | ChemoCentryx. Inc. | Aryl sulfonamides |
US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
US7335653B2 (en) | 2002-11-18 | 2008-02-26 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US8211896B2 (en) | 2002-11-18 | 2012-07-03 | Chemocentryx, Inc. | Aryl sulfonamides |
US7582661B2 (en) | 2002-11-18 | 2009-09-01 | Chemocentryx, Inc. | Aryl sulfonamides |
US7262192B2 (en) | 2003-04-29 | 2007-08-28 | Pfizer Inc. | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US8097643B2 (en) | 2003-07-30 | 2012-01-17 | Laboratorios Del Dr. Esteve S. A. | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
US7462640B2 (en) | 2003-07-30 | 2008-12-09 | Laboratorios Del Dr. Esteve S.A. | Indol-6yl sulfonamide derivatives, their preparation and their use as 5-HT-6 as modulators |
WO2005021530A1 (en) * | 2003-08-29 | 2005-03-10 | Glaxo Group Limited | 8- (1-piperazinyl)- quinoline derivatives and their use in the treatment of cns disorders |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
US8097621B2 (en) | 2003-11-24 | 2012-01-17 | Pfizer Inc. | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors |
WO2005058858A1 (en) * | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
US7820675B2 (en) | 2003-12-19 | 2010-10-26 | Biovitrum Ab | Benzofuran compounds |
EA010298B1 (en) * | 2003-12-19 | 2008-08-29 | Биовитрум Аб (Пабл) | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-htreceptor-related disorder |
US7569572B2 (en) | 2004-04-07 | 2009-08-04 | Pfizer Inc | Pyrazolo[4,3-D]pyrimidines |
WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
US8846677B2 (en) | 2005-07-04 | 2014-09-30 | High Point Pharmaceuticals, Llc | Medicaments |
US8501739B2 (en) | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
WO2007004960A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer’s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson’s disease |
WO2007004959A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease |
US7998981B2 (en) | 2005-08-12 | 2011-08-16 | Suven Life Sciences Limited | Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands |
US7923566B2 (en) | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
WO2007108743A3 (en) * | 2006-03-17 | 2007-11-15 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators ii |
WO2007108744A3 (en) * | 2006-03-17 | 2007-11-15 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators |
WO2007108743A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators ii |
WO2007108744A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators |
WO2007107373A1 (en) | 2006-03-23 | 2007-09-27 | Laboratorios Del Dr. Esteve S.A. | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
EP1837332A1 (en) * | 2006-03-23 | 2007-09-26 | Laboratorios Del Dr. Esteve, S.A. | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
US8378097B2 (en) | 2006-05-29 | 2013-02-19 | High Point Pharmaceuticals, Llc | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist |
US7960374B2 (en) | 2006-10-30 | 2011-06-14 | Proximagen Limited | Tricyclic compounds, compositions, and methods useful in the treatment or prophylaxis of 5-HT6 receptor-related disorders |
US8470830B2 (en) | 2007-01-08 | 2013-06-25 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands |
US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US8003670B2 (en) | 2007-05-03 | 2011-08-23 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands |
US8344001B2 (en) | 2007-06-11 | 2013-01-01 | High Point Pharmaceuticals, Llc | Heterocyclic H3 antagonists |
US7964627B2 (en) | 2007-10-26 | 2011-06-21 | Suven Life Sciences Limited | Amino arylsulfonamide compounds and their use as 5-HT6 ligands |
US9808455B2 (en) | 2007-12-12 | 2017-11-07 | Axovant Sciences Gmbh | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US10059691B2 (en) | 2008-04-02 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US10787437B2 (en) | 2008-04-02 | 2020-09-29 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
EP2116547A1 (en) * | 2008-05-09 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands |
WO2009135925A1 (en) * | 2008-05-09 | 2009-11-12 | Laboratorios Del Dr. Esteve, S.A. | Substituted n-imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands |
US8404720B2 (en) | 2008-09-17 | 2013-03-26 | Suven Life Sciences Limited | Aryl sulfonamide amine compounds and their use as 5-HT6 ligands |
WO2010032258A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl sulfonamide amine compounds and their use as 5-ht6 ligands |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
WO2011083487A1 (en) | 2010-01-05 | 2011-07-14 | Suven Life Sciences Limited | Sulfone compounds as 5-ht6 receptor ligands |
US9840482B2 (en) | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US11304932B2 (en) | 2015-07-15 | 2022-04-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
Also Published As
Publication number | Publication date |
---|---|
JP2003513085A (en) | 2003-04-08 |
GB9926302D0 (en) | 2000-01-12 |
EP1228066A2 (en) | 2002-08-07 |
AU1278701A (en) | 2001-05-14 |
WO2001032646A3 (en) | 2001-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1228066A2 (en) | Sulfonamide derivatives | |
US7799774B2 (en) | Quinoline derivatives and their use as 5-HT6 ligands | |
EP1497291B1 (en) | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands | |
US20040242589A1 (en) | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | |
EP1730112B1 (en) | 3-((hetero)arylsulfonyl)-8'[ (aminoalkyl)oxy]quinolines as 5-ht6 receptor antagonists for the treatment of cns disorders | |
JP2002504484A (en) | New compound | |
US7439244B2 (en) | Quinoline compounds and pharmeceutical compositions containing them | |
US7439243B2 (en) | Piperazinyl-quinoline derivatives useful for the treatment of CNS disorders | |
EP1660483B1 (en) | 8-(1-piperazinyl)-quinoline derivatives and their use in the treatment of cns disorders | |
US20040053956A1 (en) | Isoquinoline derivatives useful in the treatment of cns disorders | |
Ahmed et al. | Quinoline derivatives and their use as 5-HT6 ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000974509 Country of ref document: EP |
|
ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2001 534797 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000974509 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000974509 Country of ref document: EP |